Aurobindo Pharma plunges 8% as USFDA classifies oral solids plant as OAI

USFDA, that had conducted a Current Good Manufacturing Practice (cGMP) inspection at the company’s Unit 7 an oral solids formulation manufacturing facility from Sept 19-27, 2019, issued 7 observations